Skip to main content
Clinical Trials/ACTRN12612000276853
ACTRN12612000276853
Recruiting
Phase 4

Comparison of Immunogenicity Of Type 1 Monovalent Oral Polio Vaccine (mOPVl) Administered at Short Intervals with Type 1 Monovalent (mOPVl) And Type 1&3 Bivalent (bOPV1&3) Oral Polio Vaccine Given At Standard Intervals in Healthy Newborns in Pakistan: A Randomized Trial; Aga Khan University, Karachi

WHO0 sites800 target enrollmentMarch 8, 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
poliomyelitis
Sponsor
WHO
Enrollment
800
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 8, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
WHO

Eligibility Criteria

Inclusion Criteria

  • Infants born healthy (\> 2\.5 kg birth weight, immediate cry, no neonatal IMCI danger signs) at the study sites (home or health facility births assisted by study\-Trained Birth Attendants/other health personnel) and not planning to travel away during entire the study period (birth\-102 days).

Exclusion Criteria

  • High\-risk newborns will be excluded, as well as newborns requiring hospitalization, birth weight below 2\.5 kg, cry \>2 minutes, and with any neonatal IMNCI danger signs, residence \>30 km from study site, or family is planning to be absent during the birth \- 102 day study period. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family \- e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials